Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study
Chidamide combined with fulvestrant showed encouraging antitumor activity and tolerable toxicity in pts with HR + /HER2- advanced breast cancer that had progressed after previous endocrine therapy. Trial registration ChiCTR2100044282, registered on March 14th 2021.
Authors
- La Zou
- L. Q. Yang
- X. Tan
- T. Yang
- Y. Liu
- P. Deng
- W. Li
- Xianjun Tang
- Xiaohua Zeng
Institutions
- Chongqing University (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1186/s13058-026-02254-3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00